Dr. Klein on the Rationale to Evaluate VERU-111 in mCRPC
In Partnership With:
Eric Klein, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.
Eric Klein, MD, chairman of the Glickman Urological & Kidney Institute, as well as a staff member at the Taussig Cancer Institute, Cleveland Clinic, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer (mCRPC).
VERU-111 is an oral, cytoskeletal disruptor that acts as a taxane and inhibits microtubules, says Klein. Notably, the oral formulation of the agent should be more convenient and confer less systemic adverse effects for patients compared with traditional taxanes, Klein explains.
In prostate cancer, microtubule inhibitors, such as docetaxel and cabazitaxel (Jevtana), have demonstrated efficacy against the microtubule mitotic mechanism, Klein says. The agents have reduced disease burden and prolonged survival, adds Klein. As such, VERU-111 is a promising agent for this patient population, concludes Klein.
